Warning over killer fungus which could infect millions as it spreads across Europe
Aspergillus, a type of mould which can cause lung and breathing problems if it infects a human, may infect millions of people a year as it spreads to more northerly countries in Europe, Asia and America due to rising temperatures, the study shows.
Norman van Rhijn, the Wellcome Trust research fellow at Manchester University who co-authored the study, said the world is nearing a tipping point regarding the rise of fungal pathogens, which thrive in a large variety of environments including inside houses.
Fungal infections will be a factor in millions of deaths worldwide each year, Mr Rhijn said.
Aspergillosis, the lung disease caused by spores of Aspergillus which can spread to other human organs, is one such disease.
Speaking to the FT, Mr Van Rhijn said: 'We're talking about hundreds of thousands of lives, and continental shifts in species distributions. In 50 years, where things grow and what you get infected by is going to be completely different.'
Aspergillus can have positive benefits and is used in industrial and food production, including the fermentation of soy sauce and sake.
Inhaling its spores does not make everyone ill, but the deadly fungus can be particularly threatening to those with conditions such as asthma, cystic fibrosis or a weakened immune system.
But fungal research shows Aspergillus fumigatus could spread across an additional 77 per cent of territory by the year 2100 as a result of the world's heavy use of fossil fuels, potentially exposing nine million people in Europe to the infection, according to the FT.
The species can grow quickly in high temperatures in compost, explaining why it thrives in the 37C internal temperature of the human body.
'Its lifestyle in the natural environment may have provided Aspergillus fumigatus with the fitness advantage needed to colonise human lungs,' said professor Elaine Bignell, co-director at the MRC Centre for Medical Mycology at Exeter University.
Another species, aspergillus flavus, lives on crops and could spread to an added 16 per cent of territory in north China, Russia, Scandinavia, and Alaska by 2100, researchers added. Some existing areas in African countries and Brazil may also be made inhospitable - which could be damaging to local ecosystems.
Darius Armstrong-James, professor of infectious diseases and medical mycology at Imperial College London, told the FT: 'There are serious threats from this organism both in terms of human health and food security.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
2 hours ago
- The Independent
Almost half of NHS England waiting list patients yet to have initial appointment
Around three million people in England have had no further health care since being referred to a hospital waiting list, new data suggests. NHS England figures last month estimated 7.36 million treatments were waiting to be carried out at the end of May, relating to just under 6.23 million patients – with the analysis from MBI Health suggesting almost half of those have been left in limbo. Referring to the issue as a 'frontlog' that contributes to increasing NHS waiting list times, MBI said the problem 'has gone unchallenged for too long', with an estimated 2.99 million people waiting for their first clinical contact. MBI's analysis found that around 70% of referral to treatment pathways fall into the category of being 'unseen' since the patient's GP referred them to a specialist. Delays in making a first assessment can lead to late diagnosis, worsening symptoms and pressure on emergency services. The analysis found that ear, nose and throat (ENT), trauma and orthopaedics, gastroenterology, ophthalmology and gynaecology and obstetrics departments were consistently the specialist departments with the greatest number of patients not seen for the first time. As part of the Government's 10-year health plan, the NHS is expected to meet its target of carrying out 92% per cent of routine operations and appointments within 18 weeks by March 2029 – a target that has not been achieved for almost a decade. The latest figures show how challenging that target will be given an estimated one million of the three million unseen patients have already gone more than 18 weeks without receiving any care. 'If accurate, three million people are trapped in an invisible waiting list crisis, stuck without basic diagnostic tests of first appointments while their conditions worsen,' Rachel Power, the chief executive of the Patients Association, told the Guardian. 'The scale is staggering, as nearly half of all patients on a waiting list haven't been seen by anyone. That's not a healthcare service; that's a breakdown. 'These aren't just statistics. They're people checking their phones daily for hospital calls that never come, unable to plan their lives while their symptoms deteriorate.' Last month it was found people of working age are making up a growing proportion of those on the NHS waiting list for treatment in England. Data tables published for the first time by NHS England also show people in the most deprived parts of the country are more likely to wait more than a year to start hospital treatment than those in the least deprived. The figures, analysed by the PA news agency, showed 56.1% of those on the list at the end of June this year were of working age (defined as age 19 to 64), up from 55.8% a year ago and 55.0% in June 2022. At the same time, the proportion of people on the waiting list under the age of 19 has fallen, standing at 10.8% in June this year, down from 11.2% a year earlier and 11.9% in June 2022. The proportion who are over 65 has remained broadly unchanged at around 33.1%. People of working age are also more likely to have to wait more than a year to start treatment (3.0% of patients in this age group at the end of June) than those over 65 (2.5%). However, the proportion is the same as those under 19 (also 3.0%).
Daily Mail
4 hours ago
- Daily Mail
Trump demands UK pharmaceutical giants to lower drug costs sparking fears NHS could pay the price if they refuse
Donald Trump has demanded UK pharmaceutical giants lower prices for America and suggested charging others to make up the difference. He said if they didn't, the US would deploy 'every tool in our arsenal' to protect families from 'continued abusive drug prices', sparking fears the NHS will end up paying more. Mr Trump suggested he would use tariffs to push through higher prices if countries resisted. In May Mr Trump signed an executive order demanding drugmakers cut US medicine prices to match those abroad. Yesterday in a letter to 17 pharma companies he said he expected them to deliver on measures by September 29. He asked them to apply 'most favoured nation' pricing to Medicaid, the US health programme for people on low incomes. Mr Trump also asked drugmakers to offer new medicines at the same price in the US as in other developed countries. He said: 'Our citizens pay massively higher prices than other nations pay for the same exact pill... subsidizing socialism aboard [abroad].' British pharma companies AstraZeneca and GSK were among the recipients. Others included Eli Lilly, Johnson & Johnson, Pfizer and Sanofi. The UK Government said it would 'continue to work closely with the US to get the best deal for our pharma industry and deliver mutual benefits for both our countries'.
Daily Mail
4 hours ago
- Daily Mail
Heston Blumenthal reveals he's taking weight-loss drug Wegovy and shares fears that slimming jabs could pose a threat to the food industry
Heston Blumenthal has revealed he's taking the weight-loss drug Wegovy. The celebrity chef, 59, told how he's been taking the slimming aid to help combat the effects of his bipolar medication, having been diagnosed with type 1 bipolar in 2023. Heston also expressed his fears that the rise in popularity of weight loss jabs could pose a threat to the food industry. Speaking to Times Radio, Heston explained: 'I've put on so much weight, but it's starting to come off now', before adding that his use of the drug is a 'paradox' given the fact he's a restaurateur. The TV personality remarked how he'd lost 'eight kilos' on Wegovy so far, however, he has also dealt with side effects including brain fog, slurred speech and problems with balance. The drugs contain semaglutide, an amino acid, which suppresses appetite by mimicking a hormone telling the brain you are full up. In a new interview, the celebrity chef, 59, told how he's been taking the slimming aid to help combat the effects of his bipolar medication, having been diagnosed with type 1 bipolar back in 2023 [Boxes of Wegovy pictured] Heston issued a warning to the food industry, remarking how the continued use of the popular slimming jabs could have a detrimental affect on it. He explained: 'Wegovy, Ozempic, Mounjaro – you still enjoy food, but it stops appetite, so what's going to happen is people are going to want smaller portions.' Heston added that things were 'going to get much worse in the next six months' for restaurants, before expressing that supermarkets would also be affected. However, the food writer noted that he's 'formulating a plan' in a bid to help the food industry. Elsewhere, last month, Heston revealed he 'had thought about different ways of ending [his life]' before eventually receiving treatment for bipolar disorder. The London-born celebrity chef, who holds a total of seven Michelin stars across his restaurants, was diagnosed with type 1 bipolar after being sectioned - on the insistence of his wife, French entrepreneur Melanie Ceysson - in November 2023. Bipolar disorder is a brain disorder which causes unusual and often sudden changes in mood and energy levels. He spent two weeks heavily medicated in a psychiatric hospital and a further six weeks in a clinic, where he continued with intensive treatment and practised walking meditation. Yet, four years previously, he had already hit rock bottom and was contemplating the method he would use to take his own life. Looking back to filming the cookery show Crazy Delicious in 2019, Heston told The Times: 'I remember lying on the sofa the night before I was due to go to do the show - I didn't want to do it, because of the condition I was in - and I had thought about different ways of finishing [my life]. 'I went through a list: knife? No, can't do that. Gun? Don't have one. Rope? I don't think I could do that; wouldn't know how. It would probably slip off or whatever. 'And there was no train station anywhere near to jump in front of a train.' The father-of-four, whose first eatery, The Fat Duck, was named the best restaurant in the world in 2005, added that he didn't perceive that he was in a depressive state - even when he 'was talking about suicide or death'. He told the publication: 'I must have been in a mixed state [a period of rapid highs and lows], because I was excited about planning my funeral, planning my wake. What music I wanted, who I wanted there - I got quite excited about that.'
